ADVERTISEMENT
  About the SA Blog Network













Absolutely Maybe

Absolutely Maybe


Evidence and uncertainties about medicine and life
Absolutely Maybe Home

Is a Baby Aspirin a Day the New Apple?

The views expressed are those of the author and are not necessarily those of Scientific American.


Email   PrintPrint



Cartoon of a shelf of aspirinHis first big clue came when people started hemorrhaging after chewing gum.

Lawrence Craven did tonsil and adenoid surgery in his office. And it usually went well. But in the mid-1940s, “an alarming number of hemorrhages were evidenced in disturbing frequency,” he said.

He figured it was the aspirin chewing gum people were using for pain relief. Maybe it interfered with blood clotting. Craven tested the idea out on himself. He took 12 aspirin a day till he got a “profuse nosebleed.” Then he did it a couple more times to be sure.

And if the drug could interfere with blood clotting, Craven figured maybe it could prevent blood clots in arteries that caused heart attacks. So he started prescribing an aspirin a day to thousands of men at high risk of heart attack and recording what happened: very few heart attacks.

It was the first appearance of the “aspirin a day” practice in the medical literature. But no one followed up on Craven’s call for controlled testing of the hypothesis. Then in the 1960s, John O’Brien, a hematologist in Portsmouth, England, arrived at the same conclusion. That convinced Peter Elwood from the UK Medical Research Council to start a randomized controlled trial. The first men enrolled in 1970.

Cartoon of the apple of discord
The golden apple of discord

Ten years after that, the then-new science of meta-analysis came into its own. Richard Peto from Oxford analyzed multiple trials that together showed aspirin could prevent about a quarter of heart attacks. It led to a showdown at the FDA in 1983.

One FDA board member reportedly said the evidence in favor of aspirin was “flawed” and “all the mathematical fiddling in the world couldn’t hide that fact.” While Peto loudly whispered, “Rubbish. The man’s a fool. He’s an idiot.”

All in all, that first meeting didn’t really go all that well. It would be October 1985 before the FDA would announce that aspirin was suitable for prevention in limited circumstances.

There’s a lot more evidence now. But we’re still debating it. And it still gets very heated. In May this year, the FDA rejected an application to label aspirin as suitable for prevention of heart attack in adults across the board.

Macro-photography of aspirin crystals

Aspirin crystals (Image credit: Steve Mike Neef, via Wikimedia Commons)

Low-dose aspirin may go by the cute and cuddly adjective “baby,” but it’s a powerful drug. Even “baby” aspirin daily can cause life-threatening bleeding in the gastrointestinal tract and hemorrhagic stroke (bleeding in the brain).

Since March 2009, the U.S. Preventive Services Task Force (USPSTF) has recommended low-dose aspirin for men between the ages of 45 and 79 whose risk of a heart attack outweighs their risk of gastrointestinal hemorrhage – and for women from 55 to 79 whose risk of an ischemic stroke outweighs their risk of gastrointestinal hemorrhage. (Ischemic strokes are caused by blockages, not hemorrhage.) And they recommended against aspirin for prevention of colorectal cancer in 2007.

Aspirin’s risks remain – whatever your risk of a heart attack or stroke. So the scales on benefits versus harms can tip quite easily. It’s not clear how many people use it who aren’t at risk – or how many people who could really benefit don’t use it. It’s probably used daily by at least 1 in 5 adults in the United States – and by most people over 45 who have signs of heart disease.

Into this already complex scenario comes the issue of cancer prevention. Somehow – we don’t really know why – regular aspirin has the potential to prevent cancer. Maybe.

A couple of weeks ago, a Jack Cuzick and colleagues got a lot of media attention for their conclusion that cancer prevention tips the scales in favor of aspirin. However, many aren’t convinced. If you’re interested in more detail on this, I’ve been debating the issue with one of that review’s authors on PubMed Commons.

According to the Cuzick analyses, the benefits for the average person over the age of 50 would be roughly equivalent to their estimation of the benefit of statins. But because women have a lower risk of dying from some of the conditions affected by aspirin, the net benefit for us would be much lower. The mortality rate over a 20-year period (from 10 years of aspirin-taking) would go down by less than 0.5% for a woman and be about 2% lower for a man.

Botanical drawing of meadowsweet

The name aspirin comes from Spirea (meadowsweet) (Image credit: Johann George Sturm (1795), via Wikimedia Commons)

That would be a lot of people. But if you read one of the enthusiastic media reports, you may have thought the benefit would be more dramatic. That’s because relative risk was widely reported out of context, and as though it was for all cancers, not just some – such as by Reuters: “Cancer cases and deaths could be cut by 35 to 40 percent.”

“Baby” aspirin isn’t going to be the new “apple a day” for everybody. But it certainly is preventing a lot of heart attacks and strokes – and maybe some cancers. That the apple has something of a poisonous side, too, though, means we can expect the discord about what to do with it to continue.

Stay tuned: the USPSTF will be debating a highly-anticipated update on evidence about daily aspirin in the coming months.

~~~~

If you’re interested in more about the science of analyzing bodies of research, here are some of the related Absolutely Maybe posts: 5 Key Things to Know About Meta-Analysis and Biomedical Research: Believe It Or Not?

The cartoons are my own (Creative Commons License): more at Statistically Funny.

 

* The thoughts Hilda Bastian expresses here at Absolutely Maybe are personal, and do not necessarily reflect the views of the National Institutes of Health or the U.S. Department of Health and Human Services.

Hilda Bastian About the Author: Hilda Bastian likes thinking about bias, uncertainty and how we come to know all sorts of thing. Her day job is making clinical effectiveness research accessible. And she explores the limitless comedic potential of clinical epidemiology at her cartoon blog, Statistically Funny. Follow on Twitter @hildabast.

The views expressed are those of the author and are not necessarily those of Scientific American.





Rights & Permissions

Comments 6 Comments

Add Comment
  1. 1. Chryses 7:26 am 08/18/2014

    Ms. Bastian,

    I never did get around to posting thanks for your piece on meta-analysis back in January, so I’ll take this opportunity to do so now.

    Thanks, that was a satisfying introduction to the practice, and I found the information at the links you provided informative.

    Link to this
  2. 2. Hilda Bastian in reply to Hilda Bastian 8:10 am 08/18/2014

    Thanks, Chryses! Glad it helped – although it wasn’t entirely satisfying to me to pick only 5 issues about meta-analysis to talk about. “Another 5 things about meta-analysis” is sure to follow sometime soon.

    Link to this
  3. 3. SJCrum 7:33 pm 08/19/2014

    For information, the issue with bay aspirin, or low dose, isn’t about blood clotting, but instead, about THINNING blood. As for the clotting problem, that is entirely about taking way too much aspirin, and that then causing the blood to be too thin to clot properly.

    As for the good accomplished in good amounts taken, it can totally prevent Alzheimers, strokes, heart attacks and even the 1950′s Encephylitus problem they had with people in commas.

    As for this last one, they had patients that were in open-eyed commas and there was no other activity at all. One day they gave them a certain drug and that made them totally back into consciousness and complete normal activity. Unfortunately, that ended soon and they never did understand why that success had occurred. The reason was entirely that the drug thinned the blood and a dose of aspirin daily would have accomplished the same and better.

    By the way, with Alzheimers, etcetera, they need to stop eating beef that has blood in it and which is causing all of the arterial blockage in the first place. Even so, aspirin can do wonderful things by thinning blood. Arthritis too, if I didn’t mention that. That occurs simply by too little blood flowing.

    Link to this
  4. 4. Hilda Bastian in reply to Hilda Bastian 10:00 pm 08/20/2014

    SJCrum, the term blood-thinner is used a lot to explain anti-clotting medicines, but it’s a bit misleading. For anyone interested in the different kinds of antithrombotic meds (anticoagulants and antiplatelets), here’s a good explanation. Aspirin is, among other things (including being anti-inflammatory), an antiplatelet. Platelets (also called thrombocytes) are part of clot formation.

    Link to this
  5. 5. evelyn haskins 11:15 pm 09/1/2014

    I have a serious problem with calling low dose aspirin “Baby Aspirin”, It dies inply that it is formulated for babies, and is therefore ‘milder’.

    On the other had saliculates are common in many foodstuffs — esoecially fruits and vegetables.
    I’m sure it would be better to recommend more fruits and veggies, than to recommend aspirin.

    I knw that when I have a headache I tend to have a tomato :-) With a glass of water and a pinch of salt, it works wonders. The advantege over pure aspirin is that it also comes with its own built in viatamin C :-)

    Link to this
  6. 6. evelyn haskins 11:19 pm 09/1/2014

    PS.. I CAN spell!! It is a conspiracy between my keyboard and the Internet :-( Salicylates. Vitamin C.

    Link to this

Add a Comment
You must sign in or register as a ScientificAmerican.com member to submit a comment.

More from Scientific American

Scientific American Back To School

Back to School Sale!

12 Digital Issues + 4 Years of Archive Access just $19.99

Order Now >

X

Email this Article

X